Hypersensitivity reaction disease
MONDO:0000605An immune system disease that has basis in dysregulation of the hypersensitivity reaction, an inflammatory response to an exogenous environmental antigen or an endogenous antigen initiated by the adaptive immune system.
Also known as: allergic reaction, sensitive, sensitivity, hypersensitive, hypersensitivity, hypersensitivity reaction
886 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control OngoingThis study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis long-term study is testing the safety and effectiveness of amlitelimab, an injected drug, in over 1600 people with moderate to severe atopic dermatitis (eczema) who have already taken part in earlier amlitelimab trials. Some participants will stop treatment temporarily to se…
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill shows promise for severe eczema sufferers
Disease control OngoingThis study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental cocktail aims to silence Life-Threatening food allergies
Disease control OngoingThis early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to …
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug shows promise for stubborn hand and foot eczema in phase 3 trial
Disease control OngoingThis study tests a drug called lebrikizumab against a placebo in 221 adults and teenagers with moderate-to-severe hand and foot eczema. The treatment is given as an injection under the skin over 16 weeks. The main goal is to see if the drug can clear or nearly clear the skin rash…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Stem cells could offer new hope for severe eczema sufferers
Disease control OngoingThis Phase 2 trial tests whether a stem cell therapy called ADSTEM can safely and effectively treat moderate-to-severe atopic dermatitis (eczema). About 118 adults with long-lasting eczema that hasn't responded well to standard creams will receive either ADSTEM stem cells or a pl…
Phase: PHASE2 • Sponsor: EHL Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Promising pill may tame two skin diseases at once
Disease control ENROLLING_BY_INVITATIONThis study looks at whether a daily pill called deucravacitinib can help people who have both moderate to severe psoriasis and eczema. About 50 adults will take the drug for 16 weeks while doctors track skin improvements and side effects. The goal is to find a treatment that work…
Sponsor: Xi Tan • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New eczema drug combo enters early human testing
Disease control OngoingThis early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…
Phase: PHASE1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is …
Phase: PHASE2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to slow lung scarring in hypersensitivity pneumonitis
Disease control OngoingThis phase 4 trial tests whether adding mycophenolate mofetil (MMF) to standard prednisolone treatment works better than prednisolone alone for fibrotic hypersensitivity pneumonitis, a lung condition where scarring makes breathing hard. About 144 adults with at least 40% predicte…
Phase: PHASE4 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Eczema drug dupilumab tested for Long-Term use in kids
Disease control OngoingThis study looks at the long-term safety of dupilumab (Dupixent) in children aged 6 months to 18 years with atopic dermatitis (eczema). About 880 kids who were in earlier dupilumab studies will continue treatment. Researchers will track side effects and check if a pre-filled pen …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug BBD-1 shows promise for painful skin and kidney disease
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…
Phase: PHASE2 • Sponsor: Qifeng Zhang • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Fish allergy cure? new trial tests codfish therapy in kids
Disease control OngoingThis study tests whether giving children with fish allergy small, increasing doses of codfish protein (oral immunotherapy) can help them tolerate fish without reactions. 70 children aged 2 to 10 will receive either codfish or a placebo for 12 months, then be tested for desensitis…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New eczema drug shows promise in early trial
Disease control OngoingThis Phase 2a study tests a new drug called GIA632 in 34 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely improves skin symptoms compared to a placebo. Participants are randomly assigned to receive either the drug or a placebo, and neithe…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could supermarket peanuts and milk cure food allergies? new study investigates.
Disease control OngoingThis study tests whether giving children small daily doses of peanut or cow's milk from common foods (like cereal or whole peanuts) can help them tolerate these allergens. It involves 216 children aged 3-23 with peanut or cow's milk allergy. The goal is to see if this simple appr…
Phase: NA • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New shot could tame tough eczema
Disease control OngoingThis study tests a new drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug improves eczema symptoms by at least 75% aft…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Eczema treatment FURESTEM-AD under Long-Term watch
Disease control OngoingThis study follows 262 people with moderate-to-severe atopic dermatitis (eczema) who received an injection of FURESTEM-AD in an earlier trial. Researchers are checking for long-term side effects and tracking how well the treatment controls eczema symptoms over time. The goal is t…
Sponsor: Kang Stem Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New eczema drug shows promise for kids in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eczema drug shows promise in Long-Term safety trial for thousands
Disease control OngoingThis study looks at the long-term safety and tolerability of a drug called rocatinlimab for people with moderate-to-severe atopic dermatitis (eczema). It involves over 2,600 adults and teenagers who have already completed a previous rocatinlimab study. Researchers will monitor si…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control OngoingThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New shot could tame tough eczema in phase 2 trial
Disease control OngoingThis study tests an experimental drug called TRIV-509 in 95 adults with moderate to severe atopic dermatitis (eczema). Participants receive four doses of either TRIV-509 or a placebo, then switch to the other group. The goal is to see if TRIV-509 improves eczema symptoms and is s…
Phase: PHASE2 • Sponsor: Triveni Bio • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New pill could help kids with severe eczema
Disease control OngoingThis study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, along with standard topical steroids. The…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control OngoingThis study is testing the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive injections of amlitelimab for up to 5 years, and researchers monitor for side effects an…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Eczema drug trial could mean fewer shots for patients
Disease control OngoingThis study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. Part 1 looks at how well the drug improves skin symptoms over 24 weeks. Part 2 compares a new dosing schedule (every 12 weeks) to the current one (every 4 weeks) to see if it…
Phase: PHASE3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could bring major relief for severe eczema sufferers
Disease control OngoingThis study tests an experimental injection called TQH2722 in 500 adults with moderate to severe eczema (atopic dermatitis). The goal is to see if it can significantly reduce skin redness, itching, and rash compared to a placebo. Participants receive either the drug or a dummy sho…
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Eczema drug shows promise in keeping skin clear for a year
Disease control OngoingThis study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue the drug or receive a p…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New study tests 2-Year dupilumab treatment for Kids' eczema
Disease control OngoingThis study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dup…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Peanut allergy treatment shows promise in large study
Disease control OngoingThis study follows 500 people aged 6 months to 65 years with peanut allergy who are undergoing peanut oral immunotherapy. The goal is to see how many can tolerate a maintenance dose of 300 mg of peanut protein without symptoms within two years. Researchers also track changes in q…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests whether ATI-045 can safely reduce eczema symptoms like redness, itching, and skin patches in people with moderate-to-severe disease. About 110 adults who haven't had success with topical treatments will receive either the drug or a placebo. The main goal is to se…
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill for eczema tested in over 1,000 japanese patients
Disease control OngoingThis study tracks the safety and effectiveness of CIBINQO (abrocitinib) tablets in over 1,100 Japanese patients with atopic dermatitis (eczema) under real-world medical practice. Researchers will monitor side effects, treatment dropouts, and skin clearance over time. The goal is …
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New peanut allergy vaccine enters human testing – could it end the danger?
Disease control OngoingThis early-stage trial tests a new vaccine called VLP Peanut in 46 healthy adults and people with peanut allergy. The goal is to see if it is safe and tolerable, and to get an early look at whether it might reduce allergic reactions. Participants receive injections of the vaccine…
Phase: PHASE1 • Sponsor: Allergy Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can an asthma drug soothe skin allergies? small trial tests dupilumab
Disease control OngoingThis study tests whether dupilumab, a drug already used for eczema and asthma, can help people with allergic contact dermatitis — a skin reaction to allergens like nickel or fragrances. Seventeen adults with confirmed allergies will receive the drug, and doctors will track change…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a daily pill tame severe eczema in kids?
Disease control OngoingThis study tests whether upadacitinib (Rinvoq), a daily pill already used in older patients, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo, plus a steroid cream, for up to a year. Researcher…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New shot for eczema shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug aims to calm overactive immune system in rare disorders
Disease control OngoingThis study tests a drug called leniolisib in 12 people aged 12 to 75 with certain primary immunodeficiency disorders. The goal is to see if the drug is safe and can help control immune system problems. Participants will receive three different doses of the drug, and researchers w…
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New antibody drug shows promise for tough eczema cases
Disease control OngoingThis study tests a new drug called BAT6026 in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The drug is a monoclonal antibody given as an injection. The goal is to see if it is safe and can reduce eczema severity by…
Phase: PHASE1, PHASE2 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a smartphone app tame your allergies?
Disease control ENROLLING_BY_INVITATIONThis study tests whether digital tools can help people with allergic rhinitis (hay fever) better control their symptoms. About 240 adults will use a smartphone platform that tracks symptoms, sends reminders, and gives personalized advice. Researchers will compare their progress t…
Phase: NA • Sponsor: QHSLab, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can allergy shots work as well for kids as adults? new study aims to find out.
Disease control OngoingThis 5-year study is looking at how well a year-round allergy treatment (MATA trees or MATA grass) works for children and adults with pollen allergies, including hay fever and mild asthma. Researchers want to see if the treatment is as effective in kids as it is in adults. About …
Sponsor: Allergy Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New eczema drug shows promise in long-term real-world study
Disease control OngoingThis study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Can light therapy boost eczema treatment? new trial tests UVB plus creams
Disease control OngoingThis study tests whether adding narrowband UVB phototherapy (a type of light treatment) to optimized topical therapy (creams, ointments, and skin care advice) helps adults with moderate atopic eczema more than topical therapy alone. About 316 adults whose eczema is not well contr…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for kids with severe eczema: drug trial shows promise
Disease control OngoingThis study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Peanut patch could let allergic kids tolerate small amounts of peanut
Disease control OngoingThis study tests a daily skin patch called DBV712 (Viaskin Peanut) in 600 children aged 4-7 with peanut allergy. The patch delivers a tiny amount of peanut protein to train the immune system to be less sensitive. After 12 months, researchers check if children can safely eat more …
Phase: PHASE3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a common arthritis drug tame stubborn hand eczema?
Disease control OngoingThis study looks at how well methotrexate, a drug often used for arthritis, works for people with hand eczema. Researchers will track 50 patients to see if their skin improves and how their quality of life changes. The goal is to find better ways to manage this chronic skin condi…
Sponsor: Lone Skov • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill shows promise for severe eczema in major trial
Disease control OngoingThis study tests a new oral medication, jaktinib, for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a safe and effective…
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New eczema pill shows promise in large trial
Disease control OngoingThis study tests whether a daily pill called upadacitinib, used with a steroid cream, can safely reduce eczema symptoms like itching and redness in teens and adults with moderate-to-severe disease. About 1,500 participants took the pill or a placebo for 16 weeks. The main goals w…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New eczema drug candidate enters first human safety tests
Disease control OngoingThis early-stage trial tests the safety of a new drug called GB-7624 in 40 healthy adults. It is the first time this drug is being given to humans. The study gives single or multiple doses under the skin to see if it is safe and how the body processes it. If successful, it may ev…
Phase: PHASE1 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Eczema drug study for Kids' growth pulled before it started
Disease control TerminatedThis study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study …
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New stem cell approach could fix immune systems in kids
Disease control OngoingThis Phase II trial tests a stem cell transplant from unrelated or partially matched family donors for children and young adults with severe immune deficiencies. The stem cells are specially processed to remove certain immune cells, aiming to reduce complications. The goal is to …
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Peanut allergy vaccine? new peptide therapy aims to protect kids
Disease control OngoingThis phase 2 trial tests a new treatment called PVX108 for children and teens with peanut allergy. The treatment uses small pieces of peanut protein to help the immune system become less reactive. About 90 participants will receive either PVX108 or a placebo, and researchers will…
Phase: PHASE2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control OngoingThis phase 3 trial tests a drug called lebrikizumab, given as a shot, for people with moderate-to-severe eczema that hasn't improved with standard creams. Some participants also use a steroid cream. The study involves 301 adults and lasts about 62 weeks. Researchers are checking …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Last-Resort treatment opens for rare swallowing disorder
Disease control NO_LONGER_AVAILABLEThis program offers APT-1011, a fluticasone tablet that dissolves in the mouth, to patients aged 12 and older with eosinophilic esophagitis who cannot join other studies or have not responded to available treatments. The goal is to provide access until the drug is commercially av…
Sponsor: Ellodi Pharmaceuticals, LP • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for teens with severe eczema: drug trial shows promise
Disease control OngoingThis study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear skin. Participants receive the drug and are monitored for side effects and skin improvement over time.
Phase: PHASE3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Feeding kids tiny bits of allergens may help them beat food allergies
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving very small, daily doses of foods like peanut butter or boiled egg to children under 30 months can help them outgrow their food allergies. 500 kids with proven allergies will receive oral immunotherapy for one year, then be checked for tolerance. Th…
Phase: NA • Sponsor: Deventer Ziekenhuis • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
New pill could bring relief to eczema sufferers
Disease control ENROLLING_BY_INVITATIONThis Phase 3 trial is testing an experimental oral drug called QY201 in 460 adults with moderate to severe atopic dermatitis (eczema). Participants will take either QY201 or a placebo daily for 16 weeks. The main goals are to see if the drug can significantly clear the skin and r…
Phase: PHASE3 • Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC
-
Can eczema patients safely take less dupilumab? new trial aims to find out
Disease control OngoingThis study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The …
Phase: PHASE4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
New shot could tame tough eczema in large trial
Disease control OngoingThis Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new wa…
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
New pill could ease severe asthma attacks
Disease control OngoingThis Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lun…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Urine test may spare bladder cancer patients from frequent scopes
Diagnosis OngoingThis study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…
Sponsor: Oslo University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
Fish oil for pregnant moms may shield babies from asthma
Prevention OngoingThis study tests whether giving pregnant women fish oil supplements can prevent asthma, eczema, and allergies in their children. 800 mothers took fish oil or a placebo from week 24 of pregnancy until one week after birth. The children are then followed for several years to see if…
Phase: PHASE1 • Sponsor: Copenhagen Studies on Asthma in Childhood • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
Prenatal vitamin d may shield kids from asthma
Prevention OngoingThis study tests whether giving mothers high-dose vitamin D (2400 IU daily) from week 24 of pregnancy until one week after birth can prevent asthma symptoms like wheezing in their children. 600 mothers from the ABC cohort in Denmark are participating. The children are followed fo…
Phase: PHASE1 • Sponsor: Copenhagen Studies on Asthma in Childhood • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Baby eczema cream may stop food allergies before they start
Prevention OngoingThis study tests whether using a special skin barrier cream (Epiceram) twice a day, along with a steroid cream at the first sign of eczema, can prevent food allergies in babies who develop eczema by 12 weeks old. The goal is to see if this proactive skin care reduces the number o…
Phase: PHASE2 • Sponsor: Kari Nadeau, MD, PhD • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
Vitamin d for babies: a simple way to stop food allergies?
Prevention OngoingThis study tests whether giving vitamin D supplements to healthy, breastfed infants during their first year can lower their risk of developing food allergies. Over 2,700 babies in Australia are involved, where food allergy rates are very high. Researchers will check for allergies…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
C-Section babies get a microbiome boost to fight allergies
Prevention OngoingThis study looks at whether giving C-section babies a dose of their mother's vaginal bacteria can help prevent allergies and asthma. Researchers believe that babies born by C-section miss out on beneficial bacteria that help train the immune system. The study involves 114 infants…
Phase: EARLY_PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
New cream offers hope for kids with stubborn eczema
Symptom relief OngoingThis study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New eczema ointment enters first human tests
Symptom relief ENROLLING_BY_INVITATIONThis early-stage trial tests a new ointment called CU-10101 in 64 people, first in healthy volunteers and then in those with mild to moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug, with a preliminary look at whether it impr…
Phase: PHASE1 • Sponsor: Cutia Therapeutics(Wuxi)Co.,Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New shot shows promise for severe eczema sufferers
Symptom relief OngoingThis study tests an experimental drug called SHR-1819 in 201 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it can significantly improve skin symptoms and reduce itching. Participants receive either the drug or a placebo, and researchers track sk…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New allergy tablet could help millions breathe easier
Symptom relief OngoingThis phase 3 trial tests a daily tablet that dissolves under the tongue to treat house dust mite allergies. It includes 327 Chinese participants aged 12-65 with allergic rhinitis, with or without asthma. The goal is to see if the tablet reduces allergy symptoms and the need for o…
Phase: PHASE3 • Sponsor: ALK-Abelló A/S • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Bee glue to the rescue? propolis ointment tested for dry skin
Symptom relief OngoingThis study tests whether ointments made from propolis, a natural substance from honeybees, can improve dry, itchy skin in adults with atopic tendencies. Thirty participants will apply either a propolis ointment or a plain base ointment twice daily for four weeks. Researchers will…
Phase: NA • Sponsor: Manara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New allergy shot aims to tame dust mite misery
Symptom relief OngoingThis early-stage trial tests a new biologic drug called ASP2390, given as a skin injection, in 28 adults with house dust mite allergies. The main goal is to check safety and how the immune system responds, not yet whether it works. If successful, it could lead to a new way to eas…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New eczema drug ATTO-3712 enters early human safety trials
Symptom relief OngoingThis early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visi…
Phase: PHASE1 • Sponsor: Attovia Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to ease daily misery of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …
Phase: PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New drug targets eczema itch even when rash is mild
Symptom relief OngoingThis study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests a new medicine called EVO756 in 120 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to ease symptoms, not cure the condition.
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a cholesterol cream soothe eczema?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a cream with 2% cholesterol can help repair the skin barrier and reduce symptoms in children aged 7-17 with mild to moderate eczema. Thirty participants will apply either the cholesterol cream or a placebo twice daily for 12 weeks. Researchers will measur…
Phase: NA • Sponsor: Institute of Dermatology, Thailand • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Which wound closer is best? new study aims to reduce allergic reactions after joint surgery
Symptom relief ENROLLING_BY_INVITATIONThis study looks at 600 hip or knee replacement patients to compare three different wound closure products: Sylke adhesive dressing, Exofin skin glue, and Suture Strip Plus. The goal is to see which method causes the fewest allergic skin reactions and gives the best scar appearan…
Phase: NA • Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Can we unlabel 'Allergic' kids in the ER? new study says maybe
Symptom relief OngoingMany children are incorrectly labeled as allergic to common antibiotics like amoxicillin, often due to rashes that are not true allergies. This study tests a program in the emergency department where low-risk children receive an oral challenge to see if they can safely tolerate t…
Phase: PHASE1 • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New eczema drug shows promise in reducing itch and rash
Symptom relief OngoingThis study tests an experimental drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it can reduce itching and improve skin condition compared to a placebo. About 131 participants will receive either a low dose, high dose,…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New shot could tame birch pollen allergies, early trial hopes
Symptom relief OngoingThis Phase 2 trial tests whether an injection called DM-101PX can reduce nasal symptoms caused by birch pollen allergy. About 100 adults with birch pollen allergic rhinitis or rhinoconjunctivitis will receive either the drug or a placebo. The main goal is to see if the treatment …
Phase: PHASE2 • Sponsor: Desentum Oy • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Probiotics show promise for hay fever relief
Symptom relief OngoingThis study tests whether taking oral probiotics can reduce symptoms of allergic rhinitis (hay fever) and improve quality of life. Researchers will give probiotics to 225 people aged 6 to 65 with diagnosed allergic rhinitis and measure changes in nasal symptoms, inflammation marke…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Can Diver-Style breathing clear your stuffy nose?
Symptom relief OngoingThis study looks at whether a breathing technique used by free divers can reduce symptoms of allergic rhinitis, like nasal congestion and sneezing. Thirty adults with persistent allergies will practice the 40-minute breathing sessions. Researchers will measure symptom scores, nas…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New drug ATTO1310 tested for eczema and itch relief
Symptom relief OngoingThis early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored fo…
Phase: PHASE1 • Sponsor: Attovia Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New eczema creams show promise in small study
Symptom relief OngoingThis study tested whether Bodewell eczema products are safe and help improve skin symptoms in adults with atopic dermatitis (eczema). Fifteen participants used the products for 12 weeks. Researchers measured skin clearance and quality of life improvements.
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Which nasal spray works best for hay fever? new study compares two options
Symptom relief OngoingThis study compares two nasal sprays for moderate-to-severe allergic rhinitis (hay fever): fluticasone alone versus a combination of fluticasone and azelastine. Researchers will track symptom relief and quality of life in 61 adults over two months to see which spray works better …
Phase: PHASE4 • Sponsor: Pamukkale University • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New allergy shot for teens shows early promise
Symptom relief OngoingThis study tests a new injection called LP-003 in 6 teenagers aged 12 to 18 who have allergies like hay fever, asthma, or eczema. The main goal is to check if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and drug levels rat…
Phase: PHASE1, PHASE2 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Heat therapy zaps nasal nerves to ease stuffy nose
Symptom relief OngoingThis study tests a procedure called RhinAer that uses heat to treat the nerves in the nose for people with chronic rhinitis (long-term stuffy or runny nose). Researchers want to see if it reduces inflammation and improves symptoms like cough and post-nasal drip. About 25 adults a…
Phase: NA • Sponsor: Aerin Medical • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Bubble bath breakthrough? new study tests microbubble therapy for tough skin diseases
Symptom relief ENROLLING_BY_INVITATIONThis early study will test a special microbubble bath system (Thera-Clean) on 20 people with certain skin diseases like epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis. The goal is to see if the chemical-free bubbles can clean wounds, reduce itching, and improv…
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Could a severe asthma drug also ease hayfever symptoms?
Symptom relief OngoingThis pilot study tests whether tezepelumab, a drug already approved for severe asthma, can also reduce nasal symptoms caused by hayfever in people who have both allergic asthma and allergic rhinitis. Nineteen participants will receive monthly injections of tezepelumab for 12 mont…
Phase: PHASE2 • Sponsor: Dr. Anne Ellis • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New pill could soothe severe eczema without creams
Symptom relief OngoingThis study tests an experimental oral drug called HSK44459 in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants take the drug or a placebo twice daily for 12 weeks. The goal is to see if the drug safely reduces skin redness, swelling, and itch better tha…
Phase: PHASE2 • Sponsor: Xizang Haisco Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New shot aims to tame tough seasonal allergies
Symptom relief OngoingThis study tests an experimental injection called LP-003 in 546 adults with moderate to severe seasonal allergic rhinitis (hay fever) that standard medications don't manage well. Participants receive either the drug or a placebo, and report their nasal symptoms daily. The goal is…
Phase: PHASE3 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New combo pill aims to unblock stuffy noses better than antihistamine alone
Symptom relief TerminatedThis study was designed to see if a combination of levocetirizine (an allergy medicine) and pseudoephedrine (a decongestant) works better than levocetirizine alone for relieving nasal congestion in people with allergic rhinitis. It planned to enroll people aged 12 to 65 with the …
Phase: PHASE3 • Sponsor: Eurofarma Laboratorios S.A. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Laser zaps nose nerves to stop sniffles in new trial
Symptom relief OngoingThis study tests a laser procedure that targets nerves in the nose to relieve chronic rhinitis symptoms like runny nose, sneezing, and stuffiness. 120 adults who haven't gotten relief from standard medications will receive either the laser treatment or a sham procedure. Researche…
Phase: NA • Sponsor: Chiayi Christian Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Can a simple whitening gel erase white spots on teeth?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a 10% carbamide peroxide gel, used at home, can make white spot lesions on teeth less noticeable. About 67 adults with white spots on their front teeth will use the gel and report their satisfaction. The researchers will also check for side effects like t…
Phase: NA • Sponsor: Universidad Rey Juan Carlos • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Needle-free allergy rescue: nasal spray could replace EpiPen
Symptom relief ENROLLING_BY_INVITATIONThis study tests a new epinephrine nasal powder (FMXIN002) against the standard EpiPen injection in 50 healthy adults with allergies. Researchers will measure how quickly and effectively the nasal spray delivers epinephrine into the body and its effects on vital signs. The goal i…
Phase: PHASE1, PHASE2 • Sponsor: Nasus Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Which tray whitens better? new study tests soft vs rigid for brighter smiles
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether using a soft or rigid tray for at-home tooth whitening with 16% carbamide peroxide makes a difference in how satisfied people are, how white their teeth get, and how much tooth sensitivity or gum irritation they experience. About 100 adults with health…
Phase: NA • Sponsor: Universidad Rey Juan Carlos • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Which dental cement hurts less? new study aims to find out
Symptom relief ENROLLING_BY_INVITATIONThis study compares two types of dental cement used to attach crowns and bridges: a newer resin-modified glass ionomer cement and a conventional glass ionomer cement. The goal is to see which one causes less tooth sensitivity after the procedure. About 496 people aged 15 to 70 wi…
Phase: NA • Sponsor: Saidu College of Dentistry • Aim: Symptom relief
Last updated Jun 26, 2026 14:24 UTC
-
Allergy drops under the microscope: do they really make life better for itchy eyes?
Symptom relief OngoingThis observational study looks at 100 patients with allergic conjunctivitis who received sublingual (under-the-tongue) allergen immunotherapy. Researchers will track changes in symptoms and quality of life using a standard questionnaire over 6 months. The goal is to see if this t…
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Symptom relief
Last updated Jun 26, 2026 14:24 UTC
-
New allergy vaccine could end spring sniffles
Symptom relief OngoingThis study tests a new treatment called GNR-127 for people with seasonal allergies to birch pollen. The treatment is a protein that aims to reduce allergy symptoms like sneezing, runny nose, and itchy eyes. The trial involves 150 adults and will check for safety and how well it w…
Phase: PHASE1, PHASE2 • Sponsor: AO GENERIUM • Aim: Symptom relief
Last updated Jun 26, 2026 13:40 UTC
-
Scientists dig into the mystery of unexplained allergic shock
Knowledge-focused OngoingThis study looks at people who have severe allergic reactions (anaphylaxis), especially when the cause is unknown. Researchers will do blood tests and bone marrow biopsies to find genetic or molecular clues. The goal is to understand what goes wrong in the body, not to test a new…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Real-World study tracks elidel use in asian kids with eczema
Knowledge-focused OngoingThis study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment pe…
Sponsor: BGP Products Operations GmbH, a Viatris company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Parenting program aims to boost health in latino kids
Knowledge-focused OngoingThis study tests if a special parenting program (Attachment Biobehavioral Catch-Up) can help low-income Latino children have fewer common illnesses, better sleep, and healthier weight. About 260 mothers and their 9-month-old babies will take part. The program focuses on strengthe…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists probe immune secrets of four skin diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Dust mite asthma study aims to uncover how dupilumab works inside the body
Knowledge-focused OngoingThis study looks at how dupilumab changes the way the nose and blood respond to house dust mites in adults with allergic asthma. Participants will be exposed to dust mites in a special chamber and receive either dupilumab or a placebo. The goal is to understand the drug's effects…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Breathing in xenon: a new MRI scan to see lung damage?
Knowledge-focused OngoingThis study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…
Phase: PHASE2 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Scientists use suction blisters to peek inside skin inflammation
Knowledge-focused OngoingThis study aims to understand how inflammation works in the skin and how certain anti-inflammatory drugs (biologics) affect it. Researchers will create small suction blisters on the skin of healthy volunteers and people with skin conditions, then analyze the fluid and cells. The …
Phase: PHASE2, PHASE3 • Sponsor: Wei-Che Ko • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New imaging tricks could end guesswork for hand and foot skin conditions
Knowledge-focused OngoingThis study looked at 81 adults with either palmoplantar psoriasis or palmoplantar eczema, two skin conditions that can look very similar on the palms and soles. Researchers used two special camera techniques—polarized dermoscopy and ultraviolet-induced fluorescence dermoscopy—to …
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Cleveland clinic launches asthma research to develop better tests and treatments
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to improve how asthma is diagnosed and treated by developing new tests and targeted therapies. Researchers will enroll 60 adults with asthma to test a special oil additive and measure lung function and quality of life. The goal is to create better tools for managi…
Phase: EARLY_PHASE1 • Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Massive study tracks 2500 kids from womb to uncover allergy roots
Knowledge-focused OngoingThis study enrolls 2500 pregnant women and follows their children from before birth up to age 3 (or 6 for those who continue). Researchers collect biosamples and environmental data to identify early-life markers and biological pathways that lead to food allergy and atopic dermati…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Eczema drug study pulled before it started
Knowledge-focused TerminatedThis study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
VR training could match High-Tech mannequins for emergency drills
Knowledge-focused OngoingThis study tests whether virtual reality (VR) can train new doctors as well as high-fidelity mannequins for handling emergencies like severe allergic reactions and low oxygen levels. 124 medical interns will be randomly assigned to either VR or mannequin training, then tested on …
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Peanut allergy mystery: why do some kids outgrow it?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 200 children who have tested positive for peanut allergy but avoid eating peanuts. Researchers will use a gold-standard food challenge to see which children are truly allergic and which have outgrown their allergy by age 5. The goal is to understand if avoiding…
Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Prenatal pollution linked to baby eczema?
Knowledge-focused OngoingThis study follows 456 mothers and their children for 5 years to see if certain chemicals in the mother's blood during pregnancy are linked to the child developing eczema. Researchers will check children's skin regularly and track any eczema diagnosis. The goal is to understand p…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Lung disease study probes hidden environmental triggers
Knowledge-focused OngoingThis study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is …
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists investigate skin Bacteria's role in eczema Flare-Ups
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how bacteria living on the skin influence inflammation and skin barrier damage in people with eczema or other skin diseases. Researchers will collect skin samples and measure things like moisture loss, eczema severity, and quality of life in 100 participants. …
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists hunt for clues to childhood eczema in skin and blood
Knowledge-focused OngoingThis study looks at skin and blood samples from 505 children with eczema (atopic dermatitis) to find biological markers that explain the disease. Researchers compare these markers to those in adults to see if they are similar. The goal is to better understand what causes eczema i…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Healthy volunteers help test new injection method for eczema drug
Knowledge-focused OngoingThis early-stage study tests a new drug called SHR-1819 in 160 healthy adults to see how it enters the body when given with different injection devices. The goal is to compare the drug levels and safety between devices, not to treat any disease. Participants must be 18-55 years o…
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Severe asthma drug may boost daily steps, study hopes
Knowledge-focused OngoingThis study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Eczema gene hunt: latinx patients sought for DNA discovery
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find specific gene changes (filaggrin mutations) in 300 Latinx adults with eczema. Researchers will use advanced DNA testing to see how these changes relate to the disease. The goal is to better understand eczema in this group, not to test a new treatment.
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists probe lung 'Memory' cells to unlock asthma mysteries
Knowledge-focused OngoingThis study looks at how certain immune cells, called memory Th2 cells, that stay in the lungs may trigger allergic asthma attacks when a person breathes in allergens like cat or dust mite dander. Researchers will take samples from the airways of 37 people with mild to moderate al…
Phase: NA • Sponsor: Andrew D. Luster, M.D.,Ph.D. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Blood test may predict lung decline in rare disease
Knowledge-focused OngoingThis study is looking for markers in the blood that can predict whether a person's chronic hypersensitivity pneumonitis will get worse over time. Researchers will follow about 137 patients at 7 U.S. centers for 24 months, tracking lung function, symptoms, and CT scans. The goal i…
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Moisturizer Check-Ins may boost skin health in eczema patients
Knowledge-focused OngoingThis study looks at whether tracking how often people use moisturizer can help treat dry skin caused by eczema. Thirty adults with dry skin will receive a moisturizer and be split into three groups: one with no extra help, one with weekly surveys, and one using a device to measur…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Birth control pills and bones: a new study raises questions
Knowledge-focused TerminatedThis study aimed to look at bone health in young women aged 16 to 25 who took a specific type of birth control pill (macro-progestins) for at least six months. Researchers planned to review medical records and run blood and urine tests to see if these pills affected bone density.…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Eczema blood test could reveal hidden immune clues
Knowledge-focused OngoingThis study looks at blood inflammation in people with moderate to severe atopic dermatitis (eczema). Researchers will take blood samples before and after 3 months of treatment to see how immune signals change. The goal is to better understand the immune response in different pati…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Breast milk allergy clues: study scrapped before it began
Knowledge-focused TerminatedThis study aimed to see if common food allergens like milk, egg, and peanut can pass through breast milk and cause allergies in infants. Researchers planned to test breast milk samples and check babies for sensitization using skin prick and blood tests. However, the study was wit…
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New study tracks Dupilumab's Real-Life impact on kids with severe eczema
Knowledge-focused OngoingThis study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extr…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
10,000 eczema patients enrolled in landmark Long-Term safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis registry will follow 10,000 adults with atopic dermatitis (eczema) who are already using approved treatments. Researchers will collect data on how well the treatments work and any side effects over time. The goal is to better understand the disease, its complications, and cu…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can your Baby's surroundings trigger asthma? scientists investigate
Knowledge-focused OngoingThis study follows 499 children from birth to age 6-7 to understand how early-life factors like allergens, pollution, and microbes may lead to asthma and allergies. Parents with asthma or hay fever are included. No treatments or changes are made—just observation to uncover root c…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Pfizer launches early safety trial for new eczema drug
Knowledge-focused OngoingThis early-stage study tests the safety of PF-08049820, a medicine being developed for eczema (atopic dermatitis), in about 71 healthy adults. Participants will take single or multiple doses of the drug or a placebo, and researchers will monitor how the body processes it and whet…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists hunt for hidden bacteria behind chronic sinusitis
Knowledge-focused OngoingThis study looks at the bacteria living in the nose and sinuses of people with chronic sinusitis, allergies, and healthy individuals. By analyzing tissue samples from 285 participants, researchers hope to identify which bacteria are linked to long-term inflammation. The goal is t…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Tear and blood molecules may unlock secrets of eye allergies
Knowledge-focused OngoingThis study compares small molecules called microRNAs in the tears and blood of 40 people with allergic conjunctivitis versus healthy individuals. The goal is to find patterns that could help diagnose the condition and reveal new targets for treatment. Participants are aged 5 to 3…
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Breast Milk's hidden clues: could MicroRNAs predict baby allergies?
Knowledge-focused OngoingThis study followed 221 breastfeeding mothers and their babies to see if small molecules called microRNAs in breast milk are linked to allergies, eczema, or wheezing in the first year of life. Researchers measured these molecules in milk samples and tracked babies' health. The go…
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Cat allergy study sniffs out new insights
Knowledge-focused OngoingThis study aims to see if a special cat allergen extract (AP Cat) can cause hay fever symptoms when sprayed into the nose of people with cat allergies. Twenty volunteers—some allergic to cats, some not—will receive the extract and have their symptoms and allergy markers measured.…
Phase: NA • Sponsor: Queen's University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Brain scans reveal why tourette patients are hypersensitive to everyday stimuli
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand why many people with Tourette syndrome are overly sensitive to everyday sensations like touch or noise. Researchers will monitor brain activity, heart rate, and sweat responses in 50 adults with Tourette syndrome while they experience different sound…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Planned study on severe skin reactions withdrawn before starting
Knowledge-focused TerminatedThis study was designed to observe and compare different treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, severe skin reactions often caused by medications. Researchers planned to track outcomes like healing time and death rates across hospitals using their…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Real-world dupixent study monitors eczema patients for years
Knowledge-focused OngoingThis study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Smartphone app study to track rare swelling attacks cancelled
Knowledge-focused TerminatedThis study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. Th…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
School air check: study ties pollutants to Kids' asthma
Knowledge-focused OngoingThis study monitors indoor air quality in 500 French schoolchildren's classrooms, measuring pollutants like chemicals, allergens, and microbes. Researchers will track asthma and allergy symptoms using questionnaires and lung function tests. The goal is to understand how combinati…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Everyday ozone may harm asthma sufferers more than thought
Knowledge-focused TerminatedThis study looks at how breathing in low levels of ozone—similar to what you might encounter on a typical day in Chapel Hill—affects lung function and airway inflammation in adults with mild asthma. Researchers will compare ozone exposure to filtered air in 18 participants. The g…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Pfizer tests new drug combo in healthy volunteers
Knowledge-focused OngoingThis study looks at how a new medicine (PF-08049820) is processed by the body when taken alone or with another drug (rabeprazole). It involves 18 healthy Chinese adults aged 18-65. Participants take both medicines by mouth, and blood samples are collected to measure drug levels. …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Pfizer tests new drug interactions in healthy women
Knowledge-focused OngoingThis study looks at how a new medicine called PF-08049820 changes the way birth control pills, a sedative, and a blood thinner move through the body. It involves 16 healthy adult women who will take the drugs alone and then with PF-08049820. The results will help plan future stud…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Scientists hunt for blood clues to make nut allergy treatment safer
Knowledge-focused OngoingThis study examines blood samples from 90 children with peanut or tree nut allergies to find immune markers that show how well oral immunotherapy is working. Researchers compare kids receiving immunotherapy, those avoiding nuts, and healthy adults. The goal is to develop better w…
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New camera capsule aims to see inside the esophagus
Knowledge-focused OngoingThis study tests a new, swallowable camera capsule that takes detailed images of the esophagus. It includes people with eosinophilic esophagitis and healthy volunteers. The goal is to see if the capsule works well and is comfortable to use.
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Massive study digs into why some kids outgrow food allergies
Knowledge-focused ENROLLING_BY_INVITATIONThis research study aims to understand why some people develop food allergies and others outgrow them. Researchers at Children's Hospital of Philadelphia will collect blood samples from 5,300 people (ages 1 month to 65 years) with and without food allergies to study immune cells …
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Penicillin allergy labels may fuel superbugs, study warns
Knowledge-focused OngoingThis study looks at how having a penicillin allergy record affects treatment and antibiotic resistance in patients hospitalized with COVID-19. Many people labeled as allergic to penicillin are not truly allergic, leading to use of less effective antibiotics that can drive resista…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:45 UTC
-
Eczema cream safety watch: 8,000 kids monitored for a decade
Knowledge-focused OngoingThis study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream (pimecrolimus 1%). Over 10 years, researchers track how many develop cancer, especially lymphoma and thyroid cancer. The goal is to see if the cream raises cancer risk. No new treatment is given…
Sponsor: Bausch Health Americas, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:42 UTC